Who are Evolocumab AMD's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Repatha, Praluent (Alirocumab), Evolocumab Prefilled Syringe, Repatha®, LEQVIO, Evolocumab combined with statins.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/evolocumab-amd.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Evolocumab AMD — Competitive Intelligence Brief

Evolocumab AMD (Evolocumab AMD) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PCSK9 inhibitor monoclonal antibody. Area: Cardiovascular.

phase 3 PCSK9 inhibitor monoclonal antibody PCSK9 Cardiovascular Biologic Live · refreshed every 30 min

Target snapshot

Evolocumab AMD (Evolocumab AMD) — Amgen. Evolocumab is a PCSK9 inhibitor monoclonal antibody that binds to and inactivates PCSK9 protein, allowing LDL receptors to remain on cell surfaces and increase clearance of LDL cholesterol from the blood.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Evolocumab AMD TARGET	Evolocumab AMD	Amgen	phase 3	PCSK9 inhibitor monoclonal antibody	PCSK9
Repatha	EVOLOCUMAB	Repatha	marketed	PCSK9 Inhibitor [EPC]	PCSK9	2015-01-01
Praluent (Alirocumab)	Praluent (Alirocumab)	Federico II University	marketed	PCSK9 inhibitor (monoclonal antibody)	PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9)
Evolocumab Prefilled Syringe	Evolocumab Prefilled Syringe	University of Erlangen-Nürnberg Medical School	marketed	PCSK9 inhibitor (monoclonal antibody)	PCSK9
Repatha®	Repatha®	Sejong General Hospital	marketed	PCSK9 inhibitor (monoclonal antibody)	PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9)
LEQVIO	LEQVIO	University of Louisville	marketed	PCSK9 inhibitor (siRNA)	PCSK9 mRNA
Evolocumab combined with statins	Evolocumab combined with statins	Zibo Central Hospital	marketed	PCSK9 inhibitor (monoclonal antibody)	PCSK9

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PCSK9 inhibitor monoclonal antibody class)

Amgen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Evolocumab AMD — Competitive Intelligence Brief. https://druglandscape.com/ci/evolocumab-amd. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab